The Department of Health Research (DHR) has made some exciting progress in supporting startups and developing plans for rare disease drugs in India. One of the key achievements mentioned in their 100-Day Report is the creation of 'Med-Tech Mitra', a platform designed to assist startups and private players in securing clinical validation and upscaling services . This initiative aims to boost innovation and growth in the healthcare sector.
In addition to Med-Tech Mitra, the DHR has also implemented the 'National One Health Mission for Pandemic Preparedness' and upgraded six Viral Research and Diagnostic Laboratories (VRDLs) into Integrated Research and Diagnostic Laboratories (IRDLs) to cover a broader range of infectious diseases .
When it comes to rare disease drugs, companies like Takeda Biopharmaceuticals India Private Limited are expanding their portfolio in India. They've recently launched Cinryze, an injectable prescription medicine for the treatment of hereditary angioedema (HAE), a rare genetic condition that causes swelling in different parts of the body .
There are also various startups focused on developing innovative therapies for rare diseases. Some notable examples include:
1.Entrada Therapeutics, which is developing novel therapeutics for devastating diseases like Duchenne muscular dystrophy (DMD) .
2.Healx, which uses artificial intelligence to analyze medical research data and repurpose existing drugs to treat rare diseases .
3.Passage Bio, a fully integrated gene therapy company developing life-transforming therapies for rare monogenic central nervous system diseases .
These developments demonstrate the growing focus on supporting startups and addressing the unmet needs of individuals affected by rare diseases in India.
#DHR100DayReport
#HealthcareInnovation
#StartupsInIndia
#RareDiseaseAwareness
#OrphanDrugs
#MedTechMitra
#NationalOneHealthMission
#PandemicPreparedness
#HealthcareTransformations
#IndiaHealthcare
#Biotechnology
#PharmaceuticalAdvancements
#RareDiseaseTreatment
#HealthResearch
#HereditaryAngioedema (HAE)
#DuchenneMuscularDystrophy (DMD)
#GeneTherapy
#RareGeneticDisorders
SOURCE- ET Healthworld from Economic Times
In addition to Med-Tech Mitra, the DHR has also implemented the 'National One Health Mission for Pandemic Preparedness' and upgraded six Viral Research and Diagnostic Laboratories (VRDLs) into Integrated Research and Diagnostic Laboratories (IRDLs) to cover a broader range of infectious diseases .
When it comes to rare disease drugs, companies like Takeda Biopharmaceuticals India Private Limited are expanding their portfolio in India. They've recently launched Cinryze, an injectable prescription medicine for the treatment of hereditary angioedema (HAE), a rare genetic condition that causes swelling in different parts of the body .
There are also various startups focused on developing innovative therapies for rare diseases. Some notable examples include:
1.Entrada Therapeutics, which is developing novel therapeutics for devastating diseases like Duchenne muscular dystrophy (DMD) .
2.Healx, which uses artificial intelligence to analyze medical research data and repurpose existing drugs to treat rare diseases .
3.Passage Bio, a fully integrated gene therapy company developing life-transforming therapies for rare monogenic central nervous system diseases .
These developments demonstrate the growing focus on supporting startups and addressing the unmet needs of individuals affected by rare diseases in India.
#DHR100DayReport
#HealthcareInnovation
#StartupsInIndia
#RareDiseaseAwareness
#OrphanDrugs
#MedTechMitra
#NationalOneHealthMission
#PandemicPreparedness
#HealthcareTransformations
#IndiaHealthcare
#Biotechnology
#PharmaceuticalAdvancements
#RareDiseaseTreatment
#HealthResearch
#HereditaryAngioedema (HAE)
#DuchenneMuscularDystrophy (DMD)
#GeneTherapy
#RareGeneticDisorders
SOURCE- ET Healthworld from Economic Times
The Department of Health Research (DHR) has made some exciting progress in supporting startups and developing plans for rare disease drugs in India. One of the key achievements mentioned in their 100-Day Report is the creation of 'Med-Tech Mitra', a platform designed to assist startups and private players in securing clinical validation and upscaling services . This initiative aims to boost innovation and growth in the healthcare sector.
In addition to Med-Tech Mitra, the DHR has also implemented the 'National One Health Mission for Pandemic Preparedness' and upgraded six Viral Research and Diagnostic Laboratories (VRDLs) into Integrated Research and Diagnostic Laboratories (IRDLs) to cover a broader range of infectious diseases .
When it comes to rare disease drugs, companies like Takeda Biopharmaceuticals India Private Limited are expanding their portfolio in India. They've recently launched Cinryze, an injectable prescription medicine for the treatment of hereditary angioedema (HAE), a rare genetic condition that causes swelling in different parts of the body .
There are also various startups focused on developing innovative therapies for rare diseases. Some notable examples include:
1.Entrada Therapeutics, which is developing novel therapeutics for devastating diseases like Duchenne muscular dystrophy (DMD) .
2.Healx, which uses artificial intelligence to analyze medical research data and repurpose existing drugs to treat rare diseases .
3.Passage Bio, a fully integrated gene therapy company developing life-transforming therapies for rare monogenic central nervous system diseases .
These developments demonstrate the growing focus on supporting startups and addressing the unmet needs of individuals affected by rare diseases in India.
#DHR100DayReport
#HealthcareInnovation
#StartupsInIndia
#RareDiseaseAwareness
#OrphanDrugs
#MedTechMitra
#NationalOneHealthMission
#PandemicPreparedness
#HealthcareTransformations
#IndiaHealthcare
#Biotechnology
#PharmaceuticalAdvancements
#RareDiseaseTreatment
#HealthResearch
#HereditaryAngioedema (HAE)
#DuchenneMuscularDystrophy (DMD)
#GeneTherapy
#RareGeneticDisorders
SOURCE- ET Healthworld from Economic Times
